Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and ProteasomesDiarmuid Moran(Astellas Pharma (United States)), Carl G. Maki(Rush University Medical Center)BMC Cell BiologyMay 1, 200910.1186/1471-2121-10-32Cited by 25SaveCiteExport RISWatch citationsRelated PapersZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial|The Lancet|2023|701Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial|Nature Medicine|2023|541